Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus ZOMETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus ZOMETA.
ACTONEL WITH CALCIUM (COPACKAGED) vs ZOMETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), thereby preventing the prenylation of small GTPase signaling proteins essential for osteoclast activity.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
4 mg IV over 15 minutes every 3-4 weeks for hypercalcemia of malignancy or bone metastases.
None Documented
None Documented
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Terminal elimination half-life is approximately 146 hours (6.1 days) due to prolonged release from bone; clinical context: supports monthly dosing for osteoporosis and quarterly for Paget's disease.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 mL/min.
Renal: 50-60% of the dose excreted unchanged in urine within 24 hours; terminal elimination involves slow release from bone with subsequent renal excretion; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Bisphosphonate and Calcium Supplement
Bisphosphonate